Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li S, Han Q, Tan Y, Zhao M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. Among authors: li s, li y. Cell Cycle. 2018;17(6):801-809. doi: 10.1080/15384101.2018.1431596. Epub 2018 Apr 10. Cell Cycle. 2018. PMID: 29374999 Free PMC article.
Cell intrinsic role of COX-2 in pancreatic cancer development.
Hill R, Li Y, Tran LM, Dry S, Calvopina JH, Garcia A, Kim C, Wang Y, Donahue TR, Herschman HR, Wu H. Hill R, et al. Among authors: li y. Mol Cancer Ther. 2012 Oct;11(10):2127-37. doi: 10.1158/1535-7163.MCT-12-0342. Epub 2012 Jul 10. Mol Cancer Ther. 2012. PMID: 22784710 Free PMC article.
High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.
Kiyuna T, Murakami T, Tome Y, Kawaguchi K, Igarashi K, Zhang Y, Zhao M, Li Y, Bouvet M, Kanaya F, Singh A, Dry S, Eilber FC, Hoffman RM. Kiyuna T, et al. Among authors: li y. Oncotarget. 2016 May 31;7(22):33046-54. doi: 10.18632/oncotarget.8848. Oncotarget. 2016. PMID: 27105519 Free PMC article.
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James AW, Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, Hiroshima Y, Russell T, Eckardt MA, Yanagawa J, Federman N, Matsuyama R, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Murakami T, et al. Among authors: li y. Oncotarget. 2016 Jul 26;7(30):47556-47564. doi: 10.18632/oncotarget.9879. Oncotarget. 2016. PMID: 27286459 Free PMC article.
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K, Murakami T, Chmielowski B, Igarashi K, Kiyuna T, Unno M, Nelson SD, Russell TA, Dry SM, Li Y, Eilber FC, Hoffman RM. Kawaguchi K, et al. Among authors: li y. Oncotarget. 2016 Nov 1;7(44):71737-71743. doi: 10.18632/oncotarget.12328. Oncotarget. 2016. PMID: 27690220 Free PMC article.
Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model.
Igarashi K, Kawaguchi K, Kiyuna T, Murakami T, Miwa S, Nelson SD, Dry SM, Li Y, Singh A, Kimura H, Hayashi K, Yamamoto N, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. Among authors: li y. Cell Cycle. 2017 Jan 2;16(1):91-94. doi: 10.1080/15384101.2016.1252885. Epub 2016 Nov 10. Cell Cycle. 2017. PMID: 27830986 Free PMC article.
240,017 results
You have reached the last available page of results. Please see the User Guide for more information.